Healthcare

Medical products, health services, and related companies.

55 brands with a current stake on record.

Johnson & Johnson Orthopaedics
The orthopaedics portfolio covers joint reconstruction, trauma, spine, and sports-related injuries. Johnson & Johnson's fiscal 2025 Form 10-K still includes it in MedTech and says a separation was announced in October 2025. The filing does not use a separate company name for that portfolio.
- Controlling stakeJohnson & Johnson
LAZCLUZE
LAZCLUZE is an oral EGFR inhibitor for non-small cell lung cancer. Johnson & Johnson's fiscal 2025 Form 10-K lists it with RYBREVANT as a key Innovative Medicine product.
- Controlling stakeJohnson & Johnson
Lexum
Lexum is an eye-hospital name EssilorLuxottica includes with its European clinics in the 2025 universal registration document.
- Controlling stakeEssilorLuxottica
Liquid I.V.
Liquid I.V. is a hydration brand. Unilever's 2025 annual report lists it as a Beauty & Wellbeing Power Brand in Wellbeing.
- Controlling stakeUnilever
Medline
Medline manufactures and distributes medical supplies. It is a public company after an initial public offering.
- Minority stakeBlackstone
Mentor
Mentor makes breast aesthetics and reconstruction products. Johnson & Johnson's fiscal 2025 Form 10-K places Mentor in the MedTech surgery portfolio.
- Controlling stakeJohnson & Johnson
Metamucil
A personal-health brand in Procter & Gamble's Health Care segment. The 10-K groups it with digestive wellness.
- Controlling stakeProcter & Gamble
Neurobion
A personal-health brand in Procter & Gamble's Health Care segment. The 10-K groups it with vitamins.
- Controlling stakeProcter & Gamble
Nutrafol
Nutrafol is a hair-growth supplement brand. Unilever's 2025 annual report lists it as a Beauty & Wellbeing Power Brand and says it was acquired in 2022.
- Controlling stakeUnilever
OLLY
OLLY is a vitamins brand. Unilever's 2025 annual report lists it as a Beauty & Wellbeing Power Brand.
- Controlling stakeUnilever
OPSUMIT
OPSUMIT, and the combination OPSYNVI, are treatments for pulmonary arterial hypertension. Johnson & Johnson's fiscal 2025 Form 10-K lists them as key Innovative Medicine products.
- Controlling stakeJohnson & Johnson
Optegra
Optegra is an eye-hospital platform EssilorLuxottica names in its 2025 universal registration document.
- Controlling stakeEssilorLuxottica
Oral-B
An oral-care brand in Procter & Gamble's Health Care segment, covering toothbrushes and related products.
- Controlling stakeProcter & Gamble
Orgain
Orgain sells plant-based nutrition products. Nestlé's 2025 annual review says Nestlé further increased its majority stake in Nestlé Health Science.
- Controlling stakeNestlé
Pepto-Bismol
A personal-health brand in Procter & Gamble's Health Care segment. The 10-K groups it with digestive wellness.
- Controlling stakeProcter & Gamble
PREZISTA
PREZISTA is an antiretroviral medicine for HIV. PREZCOBIX and REZOLSTA are darunavir and cobicistat combinations. Johnson & Johnson's fiscal 2025 Form 10-K lists them as key Innovative Medicine products.
- Controlling stakeJohnson & Johnson
REMICADE
REMICADE is a treatment for immune-mediated inflammatory diseases. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.
- Controlling stakeJohnson & Johnson
RetinAI
RetinAI is an ophthalmology software company EssilorLuxottica describes in its 2025 universal registration document.
- Controlling stakeEssilorLuxottica
RYBREVANT
RYBREVANT is a treatment for certain non-small cell lung cancers, also sold as RYBREVANT FASPRO. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.
- Controlling stakeJohnson & Johnson
Shields Health Solutions
Shields Health Solutions provides specialty pharmacy services.
- Portfolio investmentSycamore Partners